| Ident. | Authors (with country if any) | Title |
|---|
| 000010 |
Renato Puppi Munhoz [Brésil] ; Hélio A. Teive [Brésil] ; Hariklia Eleftherohorinou [Royaume-Uni] ; Lachlan J. Coin [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni, Brésil] | Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease |
| 000011 |
Keyoumars Ashkan [Royaume-Uni] ; Paul Shotbolt [Royaume-Uni] ; Anthony S. David [Royaume-Uni] ; Michael Samuel [Royaume-Uni] | Deep brain stimulation: a return journey from psychiatry to neurology |
| 000012 |
Mojtaba Zarei [Royaume-Uni, Iran] ; Naroa Ibarretxe-Bilbao [Espagne] ; Yaroslau Compta [Espagne] ; Morgan Hough [Royaume-Uni] ; Carme Junque [Espagne] ; Nuria Bargallo [Espagne] ; Eduardo Tolosa [Espagne] ; Maria Jose Martí [Espagne] | Cortical thinning is associated with disease stages and dementia in Parkinson's disease |
| 000022 |
Pv Dissanayake [Royaume-Uni] ; R. Wasala [Royaume-Uni] | Wolff-parkinson-white syndrome diagnosed following binge drinking associated arrhythmia |
| 000029 |
Claire L. Tomlinson [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Charmaine Meek [Royaume-Uni] ; Clare P. Herd [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Laila Shah [Royaume-Uni] ; Catherine Sackley [Royaume-Uni] ; Katherine H O. Deane [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Natalie Ives [Royaume-Uni] | Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis |
| 000048 |
Manu Sharma ; John P A. Ioannidis [États-Unis] ; Jan O. Aasly [Norvège] ; Grazia Annesi [Italie] ; Alexis Brice [France] ; Lars Bertram [Allemagne] ; Maria Bozi [Grèce] ; Maria Barcikowska [Pologne] ; David Crosiers [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Maurizio F. Facheris ; Matthew Farrer [Canada] ; Gaetan Garraux ; Suzana Gispert [Allemagne] ; Georg Auburger ; Carles Vilari O-Güell [Canada] ; Georgios M. Hadjigeorgiou [Grèce] ; Andrew A. Hicks ; Nobutaka Hattori [Japon] ; Beom S. Jeon [Corée du Sud] ; Zygmunt Jamrozik [Pologne] ; Anna Krygowska-Wajs [Pologne] ; Suzanne Lesage [France] ; Christina M. Lill [Grèce, Allemagne] ; Juei-Jueng Lin [Taïwan] ; Timothy Lynch [Irlande (pays)] ; Peter Lichtner [Allemagne] ; Anthony E. Lang [Canada] ; Cecile Libioulle [Canada] ; Miho Murata [Japon] ; Vincent Mok [Hong Kong] ; Barbara Jasinska-Myga [Pologne] ; George D. Mellick [Australie] ; Karen E. Morrison [Royaume-Uni] ; Thomas Meitnger [Allemagne] ; Alexander Zimprich [Autriche] ; Grzegorz Opala [Allemagne] ; Peter P. Pramstaller ; Irene Pichler ; Sung Sup Park [Allemagne] ; Aldo Quattrone [Italie] ; Ekaterina Rogaeva [Canada] ; Owen A. Ross [États-Unis] ; Leonidas Stefanis [Grèce] ; Joanne D. Stockton [Royaume-Uni] ; Wataru Satake [Japon] ; Peter A. Silburn [Australie] ; Tim M. Strom [Allemagne, Canada] ; Jessie Theuns [Belgique] ; Eng- King Tan [Singapour] ; Tatsushi Toda [Japon] ; Hiroyuki Tomiyama [Japon] ; Ryan J. Uitti [États-Unis] ; Christine Van Broeckhoven [Belgique] ; Karin Wirdefeldt ; Zbigniew Wszolek [États-Unis] ; Georgia Xiromerisiou [Grèce] ; Harumi S. Yomono [Japon] ; Kuo-Chu Yueh [Taïwan] ; Yi Zhao ; Thomas Gasser ; Demetrius Maraganore [États-Unis] ; Rejko Krüger | A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants |
| 000062 |
Anne Corbett [Royaume-Uni] ; James Pickett [Royaume-Uni] ; Alistair Burns [Royaume-Uni] ; Jonathan Corcoran [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] ; Paul Edison [Royaume-Uni] ; Jim J. Hagan [Royaume-Uni] ; Clive Holmes [Royaume-Uni] ; Emma Jones [Royaume-Uni] ; Cornelius Katona [Royaume-Uni] ; Ian Kearns [Royaume-Uni] ; Patrick Kehoe [Royaume-Uni] ; Amrit Mudher [Royaume-Uni] ; Anthony Passmore [Royaume-Uni] ; Nicola Shepherd [Royaume-Uni] ; Frank Walsh [Royaume-Uni] ; Clive Ballard [Royaume-Uni] | Drug repositioning for Alzheimer's disease |
| 000067 |
Zhijun Yao [République populaire de Chine] ; Bin Hu [République populaire de Chine, Royaume-Uni] ; Lina Zhao [République populaire de Chine] ; Chuanjiang Liang [République populaire de Chine] | Analysis of Gray Matter in AD Patients and MCI Subjects Based Voxel-Based Morphometry |
| 000071 |
Jonathan R. Evans [Royaume-Uni] ; Sarah L. Mason [Royaume-Uni] ; Caroline H. Williams-Gray [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | The natural history of treated Parkinson's disease in an incident, community based cohort |
| 000076 |
T. Foltynie [Royaume-Uni] ; L. Zrinzo [Royaume-Uni] ; I. Martinez-Torres [Espagne] ; E. Tripoliti [Royaume-Uni] ; E. Petersen [États-Unis] ; E. Holl [Royaume-Uni, Autriche] ; I. Aviles-Olmos [Royaume-Uni] ; M. Jahanshahi [Royaume-Uni] ; M. Hariz [Royaume-Uni, Suède] ; P. Limousin [Royaume-Uni] | MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety |
| 000087 |
Hayriye Cagnan [Royaume-Uni] ; Kevin Dolan [Pays-Bas] ; Xuan He [Pays-Bas] ; Maria Fiorella Contarino [Pays-Bas] ; Richard Schuurman [Pays-Bas] ; Pepijn Van Den Munckhof [Pays-Bas] ; Wytse J. Wadman [Pays-Bas] ; Lo Bour [Pays-Bas] ; Hubert C F. Martens [Pays-Bas] | Automatic subthalamic nucleus detection from microelectrode recordings based on noise level and neuronal activity |
| 000088 |
Christopher Wren [Royaume-Uni] ; Melanie Vogel [Allemagne] ; Stephen Lord [Royaume-Uni] ; Dominic Abrams [Royaume-Uni] ; John Bourke [Royaume-Uni] ; Philip Rees [Royaume-Uni] ; Eric Rosenthal [Royaume-Uni] | Accuracy of algorithms to predict accessory pathway location in children with Wolff–Parkinson–White syndrome |
| 000090 |
Yan Rolland [France] ; Marc Vérin [France] ; Christine A. Payan [France] ; Simon Duchesne [Canada] ; Eduard Kraft [Allemagne] ; Till K. Hauser [Allemagne] ; Josef Jarosz [Royaume-Uni] ; Neil Deasy [Royaume-Uni] ; Luc Defevbre [France] ; Christine Delmaire [France] ; Didier Dormont [France] ; Albert C. Ludolph [Allemagne] ; Gilbert Bensimon [France] ; P Nigel Leigh [Royaume-Uni, France] | A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability |
| 000093 |
Mari Carmen Portillo [Royaume-Uni] ; Sarah Cowley [Royaume-Uni] | Working the way up in neurological rehabilitation: the holistic approach of nursing care |
| 000095 |
Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Wearing‐off scales in Parkinson's disease: Critique and recommendations |
| 000106 |
Andrew King ; Satomi Maekawa ; Istvan Bodi ; Claire Troakes [Royaume-Uni] ; Safa Al-Sarraj | Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP‐43 proteinopathies but are only rarely additionally immunopositive for phosphorylation‐dependent TDP‐43 |
| 000109 |
Elina Tripoliti [Royaume-Uni] ; Laura Strong [Royaume-Uni] ; Freya Hickey [Royaume-Uni] ; Tom Foltynie [Royaume-Uni] ; Ludvic Zrinzo [Royaume-Uni] ; Joseph Candelario [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] | Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease |
| 000120 |
Ashley H. Spencer [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Alfonso Fasano [Italie] ; Andrea E. Cavanna [Royaume-Uni] | The prevalence and clinical characteristics of punding in Parkinson's disease |
| 000126 |
Pablo Martinez-Martin [Espagne] ; Carmen Rodriguez-Blazquez [Espagne] ; Monica M. Kurtis [Espagne] ; K. Ray Chaudhuri [Royaume-Uni] | The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease |
| 000135 |
Anne Pavy-Le Traon [France] ; Gerard Amarenco [France] ; Susanne Duerr [Autriche] ; Horacio Kaufmann [États-Unis] ; Heinz Lahrmann [Autriche] ; Stephanie R. Shaftman [États-Unis] ; François Tison [France] ; Gregor K. Wenning [Autriche] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Olivier Rascol [France] | The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension |
| 000155 |
Carl E. Clarke [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? |
| 000164 |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
| 000184 |
Wassilios G. Meissner [France] ; Mark Frasier [États-Unis] ; Thomas Gasser [Allemagne] ; Christopher G. Goetz [États-Unis] ; Andres Lozano [Canada] ; Paola Piccini [Royaume-Uni] ; José A. Obeso [Espagne] ; Olivier Rascol [France] ; Anthony Schapira [Royaume-Uni] ; Valerie Voon [Royaume-Uni] ; David M. Weiner [États-Unis] ; François Tison [France] ; Erwan Bezard [France] | Priorities in Parkinson's disease research |
| 000206 |
Claudia Trenkwalder [Allemagne] ; Ralf Kohnen [États-Unis, Allemagne] ; Birgit Högl [Autriche] ; Vinod Metta [Royaume-Uni] ; Friederike Sixel-Döring [Allemagne] ; Birgit Frauscher [Autriche] ; Julia Hülsmann [États-Unis, Allemagne] ; Pablo Martinez-Martin [Espagne] ; Kallol Ray Chaudhuri [Royaume-Uni] | Parkinson's disease sleep scale—validation of the revised version PDSS‐2 |
| 000207 |
Michael J. Devine [Royaume-Uni] ; Katrina Gwinn [États-Unis] ; Andrew Singleton [États-Unis] ; John Hardy [Royaume-Uni] | Parkinson's disease and α‐synuclein expression |
| 000213 |
Fabrizio Stocchi [Italie] ; Luigi Giorgi [Royaume-Uni] ; Brian Hunter [Royaume-Uni] ; Anthony Hv Schapira [Royaume-Uni] | PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease |
| 000242 |
Julius Huebl [Allemagne] ; Thomas Schoenecker [Allemagne] ; Sandy Siegert [Allemagne] ; Christof Brücke [Allemagne] ; Gerd-Helge Schneider [Allemagne] ; Andreas Kupsch [Allemagne] ; Kielan Yarrow [Royaume-Uni] ; Andrea A. Kühn [Allemagne] | Modulation of subthalamic alpha activity to emotional stimuli correlates with depressive symptoms in Parkinson's disease |
| 000247 |
A. Jon Stoessl [Canada] ; David J. Brooks [Royaume-Uni] ; David Eidelberg [États-Unis] | Milestones in neuroimaging |
| 000251 |
Mark Hallett [États-Unis, Royaume-Uni] ; John Rothwell [Royaume-Uni] | Milestones in clinical neurophysiology |
| 000253 |
Glenda Halliday [Australie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Matthew Stern [États-Unis] | Milestones in Parkinson's disease—Clinical and pathologic features |
| 000255 |
Thomas Gasser [Allemagne] ; John Hardy [Royaume-Uni] ; Yoshikuni Mizuno [Japon] | Milestones in PD genetics |
| 000260 |
Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease |
| 000274 |
S. Sharma [Royaume-Uni] ; R. Bandopadhyay ; T. Lashley ; A. E. M. Renton [Royaume-Uni] ; A. E. Kingsbury ; R. Kumaran ; C. Kallis ; C. Vilari O-Güell ; S. S. O'Sullivan ; Andrew Lees (neurologue) [Royaume-Uni] ; T. Revesz ; N. W. Wood ; J. L. Holton | LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study |
| 000292 |
Valerie Voon [Royaume-Uni] ; Mandy Sohr [Allemagne] ; Anthony E. Lang [Canada] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Jacqueline Whetteckey [États-Unis] ; Daniel Weintraub [États-Unis] ; Glen R. Wunderlich [Canada] ; Mark Stacy [États-Unis] | Impulse control disorders in parkinson disease: A multicenter case–control study |
| 000293 |
D. Okai [Royaume-Uni] ; M. Samuel ; S. Askey-Jones [Royaume-Uni] ; A. S. David [Royaume-Uni] ; R. G. Brown [Royaume-Uni] | Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework |
| 000302 |
Pablo Martinez-Martin [Espagne] ; Martine Jeukens-Visser [Pays-Bas] ; Kelly E. Lyons [États-Unis] ; C. Rodriguez-Blazquez [Espagne] ; Caroline Selai [Royaume-Uni] ; Andrew Siderowf [États-Unis] ; Mickie Welsh [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anette Schrag [Royaume-Uni] | Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations |
| 000309 |
Omar S. Mian [Royaume-Uni] ; Susanne A. Schneider [Royaume-Uni, Allemagne] ; Petra Schwingenschuh [Royaume-Uni, Autriche] ; Kailash P. Bhatia [Royaume-Uni] ; Brian L. Day [Royaume-Uni] | Gait in SWEDDs patients: Comparison with Parkinson's disease patients and healthy controls |
| 000311 |
Tessel Boertien [Royaume-Uni, Pays-Bas] ; Ludvic Zrinzo [Royaume-Uni] ; Joshua Kahan [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Laura Mancini [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] | Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease |
| 000318 |
Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
| 000324 |
Anthony H. Schapira [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Etiology and pathogenesis of Parkinson's disease |
| 000343 |
Friederike Fritze [Norvège] ; Uwe Ehrt [Norvège] ; Hogne S Nnesyn [Norvège] ; Martin Kurz [Norvège] ; Tibor Hortobágyi [Royaume-Uni] ; Sabine Piepenstock Nore [Norvège] ; Clive Ballard [Royaume-Uni] ; Dag Aarsland [Norvège] | Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features |
| 000345 |
Helen Ling [Royaume-Uni] ; Mark Braschinsky [Estonie] ; Pille Taba [Estonie] ; Siiri-Merike Lüüs [Estonie] ; Karen Doherty [Royaume-Uni] ; Anna Hotter [Autriche] ; Werner Poewe [Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Decades of delayed diagnosis in 4 levodopa‐responsive young‐onset monogenetic parkinsonism patients |
| 000353 |
Carmen Agustín-Pav N [Royaume-Uni] ; John Parkinson [Royaume-Uni] ; Mei-See Man [Royaume-Uni] ; Angela C. Roberts [Royaume-Uni] | Contribution of the amygdala, but not orbitofrontal or medial prefrontal cortices, to the expression of flavour preferences in marmoset monkeys |
| 000363 |
Stephanie M. Van Rooden [Pays-Bas] ; Fabrice Colas [Pays-Bas] ; Pablo Martínez-Martín [Espagne] ; Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Ray K. Chaudhuri [Royaume-Uni] ; Joost N. Kok [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Clinical subtypes of Parkinson's disease |
| 000370 |
A. H. V. Schapira [Royaume-Uni] | Challenges to the development of disease‐modifying therapies in Parkinson’s disease |
| 000389 |
Viduth K. Chaugule [Royaume-Uni] ; Lynn Burchell [Royaume-Uni] ; Kathryn R. Barber [Canada] ; Ateesh Sidhu [Royaume-Uni] ; Simon J. Leslie [Royaume-Uni] ; Gary S. Shaw [Canada] ; Helen Walden [Royaume-Uni] | Autoregulation of Parkin activity through its ubiquitin‐like domain |
| 000419 |
A. E. Vanhaesebrouck [Royaume-Uni] ; G. D. Shelton [États-Unis] ; L. Garosi [Royaume-Uni] ; T. R. Harcourt-Brown [Royaume-Uni] ; J. Couturier [Royaume-Uni] ; S. Behr [Royaume-Uni] ; R. J. Harvey [Royaume-Uni] ; N. D. Jeffery [Royaume-Uni, États-Unis] ; K. Matiasek [Allemagne] ; W. F. Blakemore [Royaume-Uni] ; N. Granger [Royaume-Uni] | A Novel Movement Disorder in Related Male Labrador Retrievers Characterized by Extreme Generalized Muscular Stiffness |
| 000424 |
Ainrs Stepens [Lettonie] ; Charlotte Jane Stagg [Royaume-Uni] ; Ardis Platkjis [Lettonie] ; Marie-Hlne Boudrias [Royaume-Uni] ; Heidi Johansen-Berg [Royaume-Uni] ; Michael Donaghy [Royaume-Uni] | White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome |
| 000436 |
Pablo Garcia-Reitbck [Royaume-Uni] ; Oleg Anichtchik [Royaume-Uni] ; Arianna Bellucci [Italie] ; Mariangela Iovino [Royaume-Uni] ; Chiara Ballini [Italie] ; Elena Fineberg [Royaume-Uni] ; Bernardino Ghetti [États-Unis] ; Laura Della Corte [Italie] ; Pierfranco Spano [Italie] ; George K. Tofaris [Royaume-Uni] ; Michel Goedert [Royaume-Uni] ; Maria Grazia Spillantini [Royaume-Uni] | SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsons disease |
| 000465 |
Nicola Pavese [Royaume-Uni] ; Vinod Metta [Royaume-Uni] ; Subrata K. Bose [Royaume-Uni] ; Kallol Ray Chaudhuri [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | Fatigue in Parkinsons disease is linked to striatal and limbic serotonergic dysfunction |
| 000473 |
Wesley Thevathasan [Royaume-Uni] ; Ralph Gregory [Royaume-Uni] | Deep brain stimulation for movement disorders |
| 000481 |
Guido Alves [Norvège] ; Kolbj Rn Br Nnick [Norvège] ; Dag Aarsland [Norvège] ; Kaj Blennow [Suède] ; Henrik Zetterberg [Suède] ; Clive Ballard [Royaume-Uni] ; Martin Wilhelm Kurz [Norvège] ; Ulf Andreasson [Suède] ; Ole-Bj Rn Tysnes [Norvège] ; Jan Petter Larsen [Norvège] ; Ezra Mulugeta [Norvège, Royaume-Uni] | CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study |
| 000483 |
Nin P S. Bajaj [Royaume-Uni] ; Vamsi Gontu [Royaume-Uni] ; James Birchall [Royaume-Uni] ; James Patterson [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study |
| 000485 |
Kenya Nishioka [États-Unis] ; Mounir Kefi [Tunisie] ; Barbara Jasinska-Myga [États-Unis, Pologne] ; Christian Wider [États-Unis] ; Carles Vilari O-Güell [États-Unis] ; Owen A. Ross [États-Unis] ; Michael G. Heckman [États-Unis] ; Lefkos T. Middleton [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Rim Amouri [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Samia Ben Sassi [Tunisie] ; Mourad Zouari [Tunisie] ; Ghada El Euch [Tunisie] ; Matthew J. Farrer [États-Unis] ; Faycal Hentati [Tunisie] | A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease |
| 000490 |
David A. Gallagher [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? |
| 000499 |
Benedikt Bader [Allemagne] ; Ruth H. Walker [États-Unis] ; Mathias Vogel [Allemagne] ; Mario Prosiegel [Allemagne] ; Jacqueline Mcintosh [Royaume-Uni] ; Adrian Danek [Allemagne] | Tongue protrusion and feeding dystonia: A hallmark of chorea‐acanthocytosis |
| 000508 |
G. K Gi [Royaume-Uni] ; K P Bhatia [Royaume-Uni] ; E. Tolosa [Espagne] | The role of DAT-SPECT in movement disorders |
| 000516 |
K. Ray Chaudhuri [Royaume-Uni] ; Cristina Prieto-Jurcynska [Espagne] ; Yogini Naidu [Royaume-Uni] ; Tanya Mitra [Royaume-Uni] ; Belen Frades-Payo [Espagne] ; Susanne Tluk [Royaume-Uni] ; Anne Ruessmann [Allemagne] ; Per Odin [Allemagne] ; Graeme Macphee [Royaume-Uni] ; Fabrizio Stocchi [Italie] ; William Ondo [États-Unis] ; Kapil Sethi [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Juan Carlos Martinez Castrillo [Espagne] ; Pablo Martinez-Martin [Espagne] | The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire |
| 000530 |
Carlo Colosimo [Italie] ; Pablo Martínez-Martín [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis] | Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations |
| 000532 |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of levodopa dose equivalency reporting in Parkinson's disease |
| 000533 |
J. S. K. Kauwe [États-Unis] ; S. Bertelsen [États-Unis] ; K. Mayo [États-Unis] ; C. Cruchaga [États-Unis] ; R. Abraham [Royaume-Uni] ; P. Hollingworth [Royaume-Uni] ; D. Harold [Royaume-Uni] ; M. J. Owen [Royaume-Uni] ; J. Williams [Royaume-Uni] ; S. Lovestone [Royaume-Uni] ; J. C. Morris [États-Unis] ; A. M. Goate [États-Unis] | Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease |
| 000538 |
Katharina Wulff [Royaume-Uni] ; Silvia Gatti [Suisse] ; Joseph G. Wettstein [Suisse] ; Russell G. Foster [Royaume-Uni] | Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease |
| 000549 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
| 000553 |
Atbin Djamshidian [Royaume-Uni, Autriche] ; Ashwani Jha [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Clare Jacobson [Royaume-Uni] ; Peter Brown [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Bruno B. Averbeck [Royaume-Uni] | Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease |
| 000561 |
Hu Liang Low [Royaume-Uni] | Reply: The ‘plait sign’ of neurostimulator torsion |
| 000567 |
Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis] | Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study |
| 000569 |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease |
| 000572 |
C. A. Guevara [Royaume-Uni] ; C. R. Blain [Royaume-Uni] ; D. Stahl [Royaume-Uni] ; D. J. Lythgoe [Royaume-Uni] ; P. N. Leigh [Royaume-Uni] ; G. J. Barker [Royaume-Uni] | Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy |
| 000580 |
Giuseppe Limongelli [Royaume-Uni] ; Maite Tome-Esteban [Royaume-Uni] ; Charungthai Dejthevaporn [Royaume-Uni] ; Shamima Rahman [Royaume-Uni] ; Michael G. Hanna [Royaume-Uni] ; Perry M. Elliott [Royaume-Uni] | Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease |
| 000582 |
Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] | Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets |
| 000598 |
Marios Politis [Royaume-Uni] ; Kit Wu [Royaume-Uni] ; Sophie Molloy [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] ; K. Ray Chaudhuri [Royaume-Uni] ; Paola Piccini [Royaume-Uni] | Parkinson's disease symptoms: The patient's perspective |
| 000600 |
Laura E. Hughes [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Adrian M. Owen [Royaume-Uni] ; James B. Rowe [Royaume-Uni] | Parkinson's disease and healthy aging: Independent and interacting effects on action selection |
| 000603 |
Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets |
| 000614 |
Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junque [Espagne] ; Maria-Jose Marti [Espagne] ; Francesc Valldeoriola [Espagne] ; Pere Vendrell [Espagne] ; Nuria Bargallo [Espagne] ; Mojtaba Zarei [Royaume-Uni] ; Eduardo Tolosa [Espagne] | Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel‐based diffusion tensor imaging study |
| 000615 |
Laura Silveira-Moriyama [Royaume-Uni] ; Renato Pupi Munhoz [Brésil] ; Margarete De J. Carvalho [Brésil] ; Salmo Raskin [Brésil] ; Ekaterina Rogaeva [Canada] ; Patricia De C. Aguiar [Brésil] ; Rodrigo A. Bressan [Brésil] ; Andre C. Felicio [Brésil] ; Orlando G. P. Barsottini [Brésil] ; Luiz Augusto F. Andrade [Brésil] ; Hsin F. Chien [Brésil] ; Vincenzo Bonifati [Pays-Bas] ; Egberto R. Barbosa [Brésil] ; Helio A. Teive [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | Olfactory heterogeneity in LRRK2 related Parkinsonism |
| 000643 |
Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Alexander Gerhard [Royaume-Uni] ; Alexander Reuss [Allemagne] ; Sylvia Reinecker [Allemagne] ; Nicole Schimke [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Friederike Sixel-Döring [Allemagne] ; Birgit Herting [Allemagne] ; Christoph Kamm [Allemagne] ; Thomas Gasser [Allemagne] ; Martin Sawires [Autriche] ; Felix Geser [Autriche] ; Martin Köllensperger [Autriche] ; Klaus Seppi [Autriche] ; Manja Kloss [Allemagne] ; Martin Krause [Allemagne] ; Christine Daniels [Allemagne] ; Günther Deuschl [Allemagne] ; Silke Böttger [Allemagne] ; Markus Naumann [Allemagne] ; Axel Lipp [Royaume-Uni] ; Doreen Gruber [Allemagne] ; Andreas Kupsch [Allemagne] ; Yansheng Du [États-Unis] ; Federico Turkheimer [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Thomas Klockgether [Allemagne] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Carmen Schade-Brittinger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Karla Eggert [Allemagne] | Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) |
| 000649 |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia |
| 000655 |
Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose A. Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan I. Hariz [Royaume-Uni, Suède] ; Niall P. Quinn [Royaume-Uni] ; Jans D. Speelman [Pays-Bas] ; Alim-Louis Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie-Laure Welter [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena L. Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Jorge Guridi [Espagne] ; Anna R. Bentivoglio [Italie] ; Maria F. Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony E. Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
| 000671 |
Annu Aggarwal [Inde] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Monty Silverdale [Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Shrinivas Desai [Inde] ; Mihir Munshi [Inde] ; Darshana Sanghvi [Inde] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Mohit Bhatt [Inde] | Indian‐subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms |
| 000681 |
Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy |
| 000725 |
David J. Brooks [Royaume-Uni] | Examining Braak's hypothesis by imaging Parkinson's disease |
| 000732 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease |
| 000769 |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled trial on the effect of 10 days low‐frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease |
| 000770 |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
| 000771 |
Barbara Jasinska-Myga [États-Unis, Pologne] ; Jennifer Kachergus [États-Unis] ; Carles Vilari O-Güell [États-Unis] ; Christian Wider [États-Unis] ; Alexandra I. Soto-Ortolaza [États-Unis] ; Mounir Kefi [Tunisie] ; Lefkos T. Middleton [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Rim Amouri [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Samia Ben Sassi [Tunisie] ; Mourad Zouari [Tunisie] ; Ghada El Euch [Tunisie] ; Owen A. Ross [États-Unis] ; Faycal Hentati [Tunisie] ; Matthew J. Farrer [États-Unis] | Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa |
| 000809 |
Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni] | Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? |
| 000821 |
Daniel Weintraub [États-Unis] ; Mandy Sohr [Allemagne] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mark Stacy [États-Unis] ; Valerie Voon [Royaume-Uni] ; Jacqueline Whetteckey [États-Unis] ; Glen R. Wunderlich [Canada] ; Anthony E. Lang [Canada] | Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study |
| 000822 |
Gerassimos E. Voutsinas [Grèce] ; Eleana F. Stavrou [Grèce] ; Gerassimos Karousos [Grèce] ; Aggeliki Dasoula [Grèce] ; Adamantia Papachatzopoulou [Grèce] ; Maria Syrrou [Grèce] ; Annemieke J. M. H. Verkerk [Pays-Bas] ; Peter Van Der Spek [Pays-Bas] ; George P. Patrinos [Pays-Bas, Grèce] ; Reinhard Stöger [États-Unis, Royaume-Uni] ; Aglaia Athanassiadou [Grèce] | Allelic imbalance of expression and epigenetic regulation within the alpha‐synuclein wild‐type and p.Ala53Thr alleles in Parkinson disease |
| 000844 |
Anette Schrag [Royaume-Uni] ; Shamira Sheikh [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Caroline Selai [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Irene Litvan [États-Unis] ; Anthony E. Lang [Canada] ; James H. Bower [États-Unis] ; David J. Burn [Royaume-Uni] ; Philip Low [États-Unis] ; Marjan Jahanshahi [Royaume-Uni] | A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy |
| 000850 |
Uwe Ehrt [Norvège] ; Karl Broich [Allemagne] ; Jan Petter Larsen [Norvège] ; Clive Ballard [Royaume-Uni] ; Dag Aarsland [Norvège] | Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study |
| 000853 |
Caroline H. Williams-Gray [Royaume-Uni] ; Jonathan R. Evans [Royaume-Uni] ; An Goris [Royaume-Uni, Belgique] ; Thomas Foltynie [Royaume-Uni] ; Maria Ban [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Bhaskar S. Kolachana [États-Unis] ; Daniel R. Weinberger [États-Unis] ; Stephen J. Sawcer [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort |
| 000864 |
K. Wu [Royaume-Uni] ; M. Politis [Royaume-Uni] ; P. Piccini [Royaume-Uni] | Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management |
| 000869 |
Rosa M. Sancho [Royaume-Uni] ; Bernard M. H. Law [Royaume-Uni] ; Kirsten Harvey [Royaume-Uni] | Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways |
| 000883 |
Juliane Neumann [Royaume-Uni, Allemagne] ; Jose Bras [États-Unis, Portugal, Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Parkkinen [Royaume-Uni] ; Robin H. Lachmann [Royaume-Uni] ; Abi Li [Royaume-Uni] ; Janice Holton [Royaume-Uni] ; Rita Guerreiro [États-Unis, Portugal, Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Badmavady Segarane [Royaume-Uni] ; Andrew Singleton [États-Unis, Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease |
| 000906 |
M. Selikhova [Royaume-Uni, Russie] ; D. R. Williams [Royaume-Uni, Australie] ; P. A. Kempster [Royaume-Uni, Australie] ; J. L. Holton [Royaume-Uni] ; T. Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | A clinico-pathological study of subtypes in Parkinson's disease |
| 000915 |
Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
| 000920 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
| 000924 |
A. Q. N. Mylne [Royaume-Uni] ; C. Griffiths [Royaume-Uni] ; C. Rooney [Royaume-Uni] ; P. Doyle [Royaume-Uni] | Trends in Parkinson’s disease related mortality in England and Wales, 1993–2006 |
| 000930 |
Laura Silveira-Moriyama [Royaume-Uni] ; Aviva Petrie [Royaume-Uni] ; David R. Williams [Australie] ; Andrew Evans [Australie] ; Regina Katzenschlager [Autriche] ; Egberto R. Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of a color coded probability scale to interpret smell tests in suspected parkinsonism |
| 000947 |
A. C. Ludolph [Allemagne] ; J. Kassubek [Allemagne] ; B. G. Landwehrmeyer [Allemagne] ; E. Mandelkow [Allemagne] ; E. Mandelkow [Allemagne] ; D. J. Burn [Royaume-Uni] ; D. Caparros-Lefebvre [France] ; K. A. Frey [États-Unis] ; J. G. De Yebenes [Espagne] ; T. Gasser [Allemagne] ; P. Heutink [Pays-Bas] ; G. Höglinger [Allemagne] ; Z. Jamrozik [Pologne] ; K. A. Jellinger [Autriche] ; A. Kazantsev [États-Unis] ; H. Kretzschmar [Allemagne] ; A. E. Lang [Canada] ; I. Litvan [États-Unis] ; J. J. Lucas [Espagne] ; P. L. Mcgeer [Canada] ; S. Melquist [États-Unis] ; W. Oertel [Allemagne] ; M. Otto [Allemagne] ; D. Paviour [Royaume-Uni] ; T. Reum [Allemagne] ; A. Saint-Raymond [Royaume-Uni] ; J. C. Steele ; M. Tolnay [Suisse] ; H. Tumani [Allemagne] ; J. C. Van Swieten [Pays-Bas] ; M. T. Vanier [France] ; J. Vonsattel [États-Unis] ; S. Wagner [Allemagne] ; Z. K. Wszolek [États-Unis] | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options |
| 000963 |
Edward J. Wild [Royaume-Uni] ; Nick C. Fox [Royaume-Uni] | Serial volumetric MRI in Parkinsonian disorders |
| 000971 |
Saša R. Filipovi [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni] | Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease |
| 000975 |
Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni] | Randomized controlled trial of memantine in dementia associated with Parkinson's disease |
| 000981 |
David J. Brooks [Royaume-Uni] ; Klaus Seppi [Autriche] | Proposed neuroimaging criteria for the diagnosis of multiple system atrophy |
| 000994 |
A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 000A01 |
Vicky L. Marshall [Royaume-Uni] ; Cornelia B. Reininger [Allemagne] ; Moritz Marquardt [Allemagne] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Hani T. S. Benamer [Royaume-Uni] ; Paul Kemp [Royaume-Uni] ; David Burn [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Jamie Kulisevsky [Espagne] ; Luis Cunha [Portugal] ; Durval Costa [Portugal] ; Jan Booij [Pays-Bas] ; Klaus Tatsch [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; Gudrun Ulm [Allemagne] ; Oliver Pogarell [Allemagne] ; Helmut Höffken [Allemagne] ; Anja Gerstner [Allemagne] ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT |
| 000A03 |
Christopher H. Hawkes [Royaume-Uni] ; Kelly Del Tredici [Allemagne] ; Heiko Braak [Allemagne] | Parkinson's Disease |
| 000A17 |
Dag Aarsland [Norvège, Royaume-Uni] ; Laura Marsh [États-Unis] ; Anette Schrag [Royaume-Uni] | Neuropsychiatric symptoms in Parkinson's disease |
| 000A21 |
Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junque [Espagne] ; Eduardo Tolosa [Espagne] ; Maria-Jose Marti [Espagne] ; Francesc Valldeoriola [Espagne] ; Nuria Bargallo [Espagne] ; Mojtaba Zarei [Royaume-Uni] | Neuroanatomical correlates of impaired decision‐making and facial emotion recognition in early Parkinson’s disease |
| 000A44 |
C. E. Higham [Royaume-Uni] ; T. T. Chung [Royaume-Uni] ; J. Lawrance [Royaume-Uni] ; W. M. Drake [Royaume-Uni] ; P. J. Trainer [Royaume-Uni] | Long‐term experience of pegvisomant therapy as a treatment for acromegaly |
| 000A48 |
A. H. V. Schapira [Royaume-Uni] ; M. Emre [Turquie] ; P. Jenner [Royaume-Uni] ; Werner Poewe [Autriche] | Levodopa in the treatment of Parkinson’s disease |
| 000A54 |
Coro Paisán-Ruiz [Royaume-Uni] | LRRK2 gene variation and its contribution to Parkinson disease |
| 000A58 |
Holger Honig [Allemagne] ; Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ian Forgacs [Royaume-Uni] ; Guy C. Faye [Royaume-Uni] ; Thomas Fox [Allemagne] ; Karen Fox [Allemagne] ; Francesca Mancini [Italie] ; Margherita Canesi [Italie] ; Per Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] | Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life |
| 000A64 |
David J. Brooks [Royaume-Uni] | Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography |
| 000A70 |
Christine Klein [Allemagne, Canada] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Anthony E. Lang [Canada] | Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond |
| 000A86 |
Sarah Teixeira Camargos [Brésil] ; Leonardo Oliveira Dornas [Brésil] ; Parastoo Momeni [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Andrew Singleton [États-Unis] ; Francisco Cardoso [Brésil] | Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations |
| 000B04 |
H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
| 000B05 |
H. F. Harbo [Norvège] ; J. Finsterer [Autriche] ; J. Baets [Belgique] ; C. Van Broeckhoven [Belgique] ; S. Di Donato [Italie] ; B. Fontaine [France] ; P. De Jonghe [Belgique] ; A. Lossos [Israël] ; T. Lynch [Irlande (pays)] ; C. Mariotti [Italie] ; L. Schöls [Allemagne] ; A. Spinazzola [Italie] ; Z. Szolnoki [Hongrie] ; S. J. Tabrizi [Royaume-Uni] ; C. Tallaksen [Norvège] ; M. Zeviani [Italie] ; J. Burgunder [Suisse] ; T. Gasser [Allemagne] | EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias |
| 000B06 |
Marian L. Evatt [États-Unis] ; K. Ray Chaudhuri [Royaume-Uni] ; Kelvin L. Chou [États-Unis] ; Ester Cubo [Espagne] ; Vanessa Hinson [États-Unis] ; Katie Kompoliti [États-Unis] ; Chengwu Yang [États-Unis] ; Werner Poewe [États-Unis] ; Olivier Rascol [Autriche] ; Cristina Sampaio [France, Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease |
| 000B19 |
Susan Howell [Royaume-Uni] ; Elina Tripoliti [Royaume-Uni] ; Tim Pring [Royaume-Uni] | Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study |
| 000B29 |
Susanne A. Schneider [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; John Hardy [Royaume-Uni] | Complicated recessive dystonia parkinsonism syndromes |
| 000B43 |
A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease |
| 000B56 |
Gráinne C. O Eeffe [Royaume-Uni] ; Andrew W. Michell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | Biomarkers in Huntington's and Parkinson's Disease |
| 000B75 |
Laura Silveira-Moriyama [Royaume-Uni] ; Dharshana Sirisena [Sri Lanka] ; Pasan Gamage [Sri Lanka] ; Ranjanie Gamage [Sri Lanka] ; Rohan De Silva [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka |
| 000B76 |
Edward J. Newman [Royaume-Uni] ; Kieran Breen [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland |
| 000C20 |
C. Warren Olanow [États-Unis] ; Karl Kieburtz [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] | Why have we failed to achieve neuroprotection in Parkinson's disease? |
| 000C22 |
Helene Plun-Favreau [Royaume-Uni] ; Sonia Gandhi [Royaume-Uni] ; Alison Wood-Kaczmar [Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Zhi Yao [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | What Have PINK1 and HtrA2 Genes Told Us about the Role of Mitochondria in Parkinson's Disease? |
| 000C28 |
D R Williams [Royaume-Uni] ; J D Warren [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism |
| 000C39 |
Laura Silveira-Moriyama [Royaume-Uni] ; Margarete De Jesus Carvalho [Brésil] ; Regina Katzenschlager [Autriche] ; Aviva Petrie [Royaume-Uni] ; Ronald Ranvaud [Brésil] ; Egberto Reis Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil |
| 000C43 |
Christopher H. Hawkes [Royaume-Uni] | The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? |
| 000C47 |
M. E. Kalaitzakis [Royaume-Uni] ; M. B. Graeber [Royaume-Uni] ; S. M. Gentleman [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni] | The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α‐synuclein staging |
| 000C50 |
Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
| 000C51 |
Andrew Lees (neurologue) [Royaume-Uni] ; Marianna Selikhova [Royaume-Uni] ; Luiz Augusto Andrade [Brésil] ; Charles Duyckaerts [France] | The black stuff and Konstantin Nikolaevich Tretiakoff |
| 000C59 |
Sonja Scholz [États-Unis, Royaume-Uni] ; Andrew Singleton [États-Unis] | Susceptibility genes in movement disorders |
| 000C76 |
Pablo Martinez-Martin [Espagne] ; Martine Visser [Pays-Bas] ; Carmen Rodriguez-Blazquez [Espagne] ; Johan Marinus [Pays-Bas] ; K. Ray Chaudhuri [Royaume-Uni] ; Jacobus J. Van Hilten [Pays-Bas] | SCOPA‐sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease |
| 000C87 |
K. Ray Chaudhuri [Royaume-Uni] ; P. Martinez-Martin [Espagne] | Quantitation of non‐motor symptoms in Parkinson’s disease |
| 000C89 |
Susanne Hempel [États-Unis] ; Gill Norman [Royaume-Uni] ; Su Golder [Royaume-Uni] ; Raquel Aguiar-Ibá Ez [Royaume-Uni] ; Alison Eastwood [Royaume-Uni] | Psychosocial interventions for non‐professional carers of people with Parkinson’s disease: a systematic scoping review |
| 000C95 |
L. Ishihara-Paul [Royaume-Uni] ; N. W. J. Wainwright [Royaume-Uni] ; K. Khaw [Royaume-Uni] ; R. N. Luben [Royaume-Uni] ; A. A. Welch [Royaume-Uni] ; N. E. Day [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; P. G. Surtees [Royaume-Uni] | Prospective association between emotional health and clinical evidence of Parkinson’s disease |
| 000C96 |
A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
| 000C98 |
Peter Jenner [Royaume-Uni] | Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities |
| 000D05 |
David Stuckler [Royaume-Uni] | Population Causes and Consequences of Leading Chronic Diseases: A Comparative Analysis of Prevailing Explanations |
| 000D14 |
Hani T. S. Benamer [Royaume-Uni] ; Rajith De Silva [Royaume-Uni] ; Khurram A. Siddiqui ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease in Arabs: A systematic review |
| 000D25 |
Rhona Mirsky [Royaume-Uni] ; Ashwin Woodhoo [Royaume-Uni] ; David B. Parkinson [Royaume-Uni] ; Peter Arthur-Farraj [Royaume-Uni] ; Ambily Bhaskaran [Royaume-Uni] ; Kristján R. Jessen [Royaume-Uni] | Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation |
| 000D28 |
Sean S. O'Sullivan [Royaume-Uni] ; David R. Williams [Royaume-Uni, Australie] ; David A. Gallagher [Royaume-Uni] ; Luke A. Massey [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study |
| 000D38 |
Kristján R. Jessen [Royaume-Uni] ; Rhona Mirsky [Royaume-Uni] | Negative regulation of myelination: Relevance for development, injury, and demyelinating disease |
| 000D43 |
Marwan I. Hariz [Royaume-Uni, Suède] ; Stig Rehncrona [Suède] ; Niall P. Quinn [Royaume-Uni] ; Johannes D. Speelman [Pays-Bas] ; Carin Wensing [Pays-Bas] | Multicenter study on deep brain stimulation in Parkinson's disease: An independent assessment of reported adverse events at 4 years |
| 000D66 |
J. Alegre-Abarrategui ; O. Ansorge [Royaume-Uni] ; M. Esiri [Royaume-Uni] ; R. Wade-Martins | LRRK2 is a component of granular alpha‐synuclein pathology in the brainstem of Parkinson's disease |
| 000D67 |
X. An [République populaire de Chine] ; R. Peng [République populaire de Chine] ; T. Li [République populaire de Chine, Royaume-Uni] ; J. Burgunder [République populaire de Chine, Singapour] ; Y. Wu [République populaire de Chine] ; W. Chen [République populaire de Chine] ; J. Zhang [République populaire de Chine] ; Y. Wang [République populaire de Chine] ; Y. Xu [République populaire de Chine] ; Y. Gou [République populaire de Chine] ; G. Yuan [République populaire de Chine] ; Z. Zhang [République populaire de Chine] | LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China |
| 000D84 |
R. John Dobbs [Royaume-Uni] ; Sylvia M. Dobbs [Royaume-Uni] ; Clive Weller [Royaume-Uni] ; André Charlett [Royaume-Uni] ; Ingvar T. Bjarnason ; Alan Curry [Royaume-Uni] ; David S. Ellis ; Mohammad A. A. Ibrahim ; Maria V. Mccrossan ; John O'Donohue ; Robert J. Owen [Royaume-Uni] ; Norman L. Oxlade [Royaume-Uni] ; Ashley B. Price [Royaume-Uni] ; Jeremy D. Sanderson [Royaume-Uni] ; Malur Sudhanva [Royaume-Uni] ; John Williams [Royaume-Uni] | Helicobacter Hypothesis for Idiopathic Parkinsonism: Before and Beyond |
| 000D90 |
Javier Simon-Sanchez [États-Unis, Espagne] ; Sonja Scholz [États-Unis, Royaume-Uni] ; Maria Del Mar Matarin [États-Unis] ; Hon-Chung Fung [Royaume-Uni, États-Unis] ; Dena Hernandez [États-Unis] ; J Raphael Gibbs [Royaume-Uni, États-Unis] ; Angela Britton [États-Unis] ; John Hardy [Royaume-Uni] ; Andrew Singleton [États-Unis] | Genomewide SNP assay reveals mutations underlying Parkinson disease |
| 000D96 |
Peter Jenner [Royaume-Uni] | Functional models of Parkinson's disease: A valuable tool in the development of novel therapies |
| 000E13 |
Anthony H. V. Schapira [Royaume-Uni] ; C. Warren Olanow [États-Unis] | Drug selection and timing of initiation of treatment in early Parkinson's disease |
| 000E33 |
Angelo Antonini [Italie] ; Patrizia Berto [Italie] ; Stefania Lopatriello [Italie] ; Filippo Tamma [Italie] ; Lieven Annemans [Belgique] ; Mike Chambers [Royaume-Uni] | Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy |
| 000E37 |
Coro Paisán-Ruíz [États-Unis] ; Priti Nath [États-Unis] ; Nicole Washecka [États-Unis] ; J. Raphael Gibbs [États-Unis, Royaume-Uni] ; Andrew B. Singleton [États-Unis] | Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls |
| 000E45 |
J. C. Möller [Allemagne] ; K. M. Eggert [Allemagne] ; M. Unger [Allemagne] ; P. Odin [Allemagne] ; K. R. Chaudhuri [Royaume-Uni] ; W. H. Oertel [Allemagne] | Clinical risk–benefit assessment of dopamine agonists |
| 000E47 |
Daisy L. Whitehead [Royaume-Uni] ; Ann D. M. Davies [Royaume-Uni] ; Jeremy R. Playfer [Royaume-Uni] ; Christopher J. Turnbull [Royaume-Uni] | Circadian rest‐activity rhythm is altered in Parkinson's disease patients with hallucinations |
| 000E52 |
Jo Knight [Royaume-Uni] ; David Curtis [Royaume-Uni] ; Pak C. Sham [Royaume-Uni, Hong Kong] | CLUMPHAP: a simple tool for performing haplotype‐based association analysis |
| 000E57 |
L. Bet [Italie] ; S. R. Bareggi [Italie] ; F. Pacei [Italie] ; G. Bondiolotti [Italie] ; G. Meola [Italie] ; A. H. V. Schapira [Royaume-Uni] | Bimodal administration of entacapone in Parkinson’s disease patients improves motor control |
| 000E64 |
Carl E. Clarke [Royaume-Uni] | Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
| 000E69 |
Bart P. C. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Andrew J. Church [Royaume-Uni] ; Davide Martino [Royaume-Uni, Italie] ; Paul M. Candler [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Gavin Giovannoni [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] | Antineuronal antibodies in Parkinson's disease |
| 000F12 |
Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Andrew Evans [Royaume-Uni] ; Flavia Fontes [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Svetoslav Gacinovic [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Durval Costa [Royaume-Uni, Portugal] | [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease |
| 000F18 |
Andrew Lees (neurologue) [Royaume-Uni] | Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday |
| 000F22 |
Morten L. Kringelbach [Royaume-Uni, Danemark] ; Ned Jenkinson [Royaume-Uni] ; Sarah L. F. Owen [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Translational principles of deep brain stimulation |
| 000F37 |
Kallol Ray Chaudhuri [Royaume-Uni] ; Pablo Martinez-Martin [Espagne] ; Richard G. Brown [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie] ; Per Odin [Allemagne] ; William Ondo [États-Unis] ; Kazuo Abe [Japon] ; Graeme Macphee [Royaume-Uni] ; Doug Macmahon [Royaume-Uni] ; Paolo Barone [Italie] ; Martin Rabey [Israël] ; Alison Forbes [Royaume-Uni] ; Kieran Breen [Royaume-Uni] ; Susanne Tluk [Royaume-Uni] ; Yogini Naidu [Royaume-Uni] ; Warren Olanow [États-Unis] ; Adrian J. Williams [Royaume-Uni] ; Sue Thomas [Royaume-Uni] ; David Rye [États-Unis] ; Yoshio Tsuboi [Japon] ; Annette Hand [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study |
| 000F44 |
An Goris [Royaume-Uni, Belgique] ; Caroline H. Williams-Gray [Royaume-Uni] ; Graeme R. Clark [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] ; Simon J. G. Lewis [Royaume-Uni] ; Joanne Brown [Royaume-Uni] ; Maria Ban [Royaume-Uni] ; Maria G. Spillantini [Royaume-Uni] ; Alastair Compston [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Patrick F. Chinnery [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Stephen J. Sawcer [Royaume-Uni] | Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease |
| 000F59 |
Lianna Ishihara [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Liling Warren [États-Unis] ; Rim Amouri [Tunisie] ; Kelly Lyons [États-Unis] ; Catherine Wielinski [États-Unis] ; Christine Hunter [États-Unis] ; Jina E. Swartz [Royaume-Uni] ; Ramu Elango [Royaume-Uni] ; P. Anthony Akkari [États-Unis] ; David Leppert [Royaume-Uni] ; Linda Surh [Royaume-Uni] ; Kevin H. Reeves [États-Unis] ; Siwan Thomas [Royaume-Uni] ; Leigh Ragone [États-Unis] ; Nobutaka Hattori [Japon] ; Rajesh Pahwa [États-Unis] ; Joseph Jankovic [États-Unis] ; Martha Nance [États-Unis] ; Alan Freeman [États-Unis] ; Neziha Gouider-Khouja [Tunisie] ; Mounir Kefi [Tunisie] ; Mourad Zouari [Tunisie] ; Samia Ben Sassi [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Ghada El Euch-Fayeche [Tunisie] ; Lefkos Middleton [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Ray L. Watts [États-Unis] ; Faycal Hentati [Tunisie] | Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families |
| 000F60 |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole |
| 000F68 |
G. Waldemar [Danemark] ; B. Dubois [France] ; M. Emre [Turquie] ; J. Georges [Luxembourg (pays)] ; I. G. Mckeith [Royaume-Uni] ; M. Rossor [Royaume-Uni] ; P. Scheltens [Pays-Bas] ; P. Tariska [Hongrie] ; B. Winblad [Suède] | Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline |
| 000F69 |
Anette Schrag [Royaume-Uni] ; Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Bernhard Bornschein [Autriche] ; Uwe Siebert [Autriche, États-Unis] ; Niall P. Quinn [Royaume-Uni] | Rate of clinical progression in Parkinson's disease. A prospective study |
| 000F72 |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
| 000F84 |
Andrew J. Lawrence [Royaume-Uni] ; Andrew D. Blackwell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Francesca Spagnolo [Italie] ; Luke Clark [Royaume-Uni] ; Michael R. F. Aitken [Royaume-Uni] ; Barbara J. Sahakian [Royaume-Uni] | Predictors of punding in Parkinson's disease: Results from a questionnaire survey |
| 000F90 |
David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series |
| 001050 |
Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
| 001057 |
Lianna S. Ishihara [Royaume-Uni] ; Anne Cheesbrough [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Estimated life expectancy of Parkinson’s patients compared with the UK population |
| 001072 |
Dominic C. Paviour [Royaume-Uni] ; John S. Thornton [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; H. Rolf J Ger [Royaume-Uni] | Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy |
| 001075 |
Bruno Dubois [France] ; David Burn [Royaume-Uni] ; Christopher Goetz [États-Unis] ; Dag Aarsland [Norvège] ; Richard G. Brown [Royaume-Uni] ; Gerald A. Broe [Australie] ; Dennis Dickson [États-Unis] ; Charles Duyckaerts [France] ; Jefferey Cummings [États-Unis] ; Serge Gauthier [Canada] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Yoshikuni Mizuno [Japon] ; Ian G. Mckeith [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Murat Emre [Turquie] | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force |
| 001076 |
Bernard Ravina [États-Unis] ; Karen Marder [États-Unis] ; Hubert H. Fernandez [États-Unis] ; Joseph H. Friedman [États-Unis] ; William Mcdonald [États-Unis] ; Diane Murphy [États-Unis] ; Dag Aarsland [États-Unis] ; Debra Babcock [États-Unis] ; Jefferey Cummings [États-Unis] ; Jean Endicott [États-Unis] ; Stewart Factor [États-Unis] ; Wendy Galpern [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Laura Marsh [États-Unis] ; Mark Stacy [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Valerie Voon [États-Unis] ; Christopher Goetz [États-Unis] | Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group |
| 001080 |
Anette Schrag [Royaume-Uni] ; Paolo Barone [Italie] ; Richard G. Brown [Royaume-Uni] ; Albert F. G. Leentjens [Pays-Bas] ; William M. Mcdonald [États-Unis] ; Sergio Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Depression rating scales in Parkinson's disease: Critique and recommendations |
| 001098 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Richard Brown [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Charles Duyckaerts [France] ; Yoshikino Mizuno [Japon] ; Gerald Anthony Broe [Australie] ; Jeffrey Cummings [États-Unis] ; Dennis W. Dickson [États-Unis] ; Serge Gauthier [Canada] ; Jennifer Goldman [États-Unis] ; Christopher Goetz [États-Unis] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Ian Mckeith [Royaume-Uni] ; Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; Christina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Bruno Dubois [France] | Clinical diagnostic criteria for dementia associated with Parkinson's disease |
| 001101 |
Paul T. Francis [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies |
| 001105 |
Adolfo Mínguez-Castellanos [Espagne] ; Francisco Escamilla-Sevilla [Espagne] ; Gary R. Hotton [Royaume-Uni] ; Juan J. Toledo-Aral [Espagne] ; Ángel Ortega-Moreno [Espagne] ; Sim N Méndez-Ferrer [Espagne] ; José M. Martín-Linares [Espagne] ; Majed J. Katati [Espagne] ; Pablo Mir [Espagne] ; Javier Villadiego [Espagne] ; Miguel Meersmans [Espagne] ; Miguel Pérez-García [Espagne] ; David J. Brooks [Royaume-Uni] ; Ventura Arjona [Espagne] ; José L Pez-Barneo [Espagne] | Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study |
| 001136 |
D. Grosset [Royaume-Uni] ; L. Taurah [Royaume-Uni] ; D J Burn [Royaume-Uni] ; D. Macmahon [Royaume-Uni] ; A. Forbes [Royaume-Uni] ; K. Turner [Royaume-Uni] ; A. Bowron [Royaume-Uni] ; R. Walker [Royaume-Uni] ; L. Findley [Royaume-Uni] ; O. Foster [Royaume-Uni] ; K. Patel [Royaume-Uni] ; C. Clough [Royaume-Uni] ; B. Castleton [Royaume-Uni] ; S. Smith [Royaume-Uni] ; G. Carey [Royaume-Uni] ; T. Murphy [Royaume-Uni] ; J. Hill [Royaume-Uni] ; U. Brechany [Royaume-Uni] ; P. Mcgee [Royaume-Uni] ; S. Reading [Royaume-Uni] ; G. Brand [Royaume-Uni] ; L. Kelly [Royaume-Uni] ; K. Breen [Royaume-Uni] ; S. Ford [Royaume-Uni] ; M. Baker [Royaume-Uni] ; A. Williams [Royaume-Uni] ; J. Hearne [Royaume-Uni] ; N. Qizilbash [Royaume-Uni] ; K Ray Chaudhuri [Royaume-Uni] | A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis |
| 001137 |
Ruth M. Pickering [Royaume-Uni] ; Yvette A. M. Grimbergen [Pays-Bas] ; Una Rigney [Royaume-Uni] ; Ann Ashburn [Royaume-Uni] ; Gordon Mazibrada [Royaume-Uni] ; Brian Wood [Royaume-Uni] ; Peggy Gray [Canada] ; Graham Kerr [Australie] ; Bastiaan R. Bloem [Pays-Bas] | A meta‐analysis of six prospective studies of falling in Parkinson's disease |
| 001148 |
S. Gandhi ; M. M. K. Muqit ; L. Stanyer ; D. G. Healy ; P. M. Abou-Sleiman ; I. Hargreaves ; S. Heales ; M. Ganguly ; L. Parsons ; Andrew Lees (neurologue) [Royaume-Uni] ; D. S. Latchman [Royaume-Uni] ; J. L. Holton ; N. W. Wood ; T. Revesz | PINK1 protein in normal human brain and Parkinson's disease |
| 001161 |
Lianna Ishihara [Royaume-Uni] ; Carol Brayne [Royaume-Uni] | What is the evidence for a premorbid parkinsonian personality: A systematic review |
| 001177 |
Anthony H. V. Schapira [Royaume-Uni, Espagne] ; Jose Obeso [Royaume-Uni, Espagne] | Timing of treatment initiation in Parkinson's disease: A need for reappraisal? |
| 001180 |
M. Sharma [Allemagne] ; J C Mueller [Allemagne] ; A. Zimprich [Autriche] ; P. Lichtner [Allemagne] ; A. Hofer [Allemagne] ; P. Leitner [Allemagne] ; S. Maass [Allemagne] ; D. Berg [Allemagne] ; A. Dürr [France] ; V. Bonifati [Italie] ; G. De Michele [Pays-Bas] ; B. Oostra [Italie] ; A. Brice [France] ; N W Wood [Royaume-Uni] ; B. Muller-Myhsok [Allemagne] ; T. Gasser [Allemagne] | The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations |
| 001185 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 001205 |
Alexander L. Green [Royaume-Uni] ; Richard G. Bittar [Royaume-Uni] ; Peter Bain [Royaume-Uni] ; Richard B. Scott [Royaume-Uni] ; Carol Joint [Royaume-Uni] ; Ralph Gregory [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | STN vs. Pallidal Stimulation in Parkinson Disease: Improvement With Experience and Better Patient Selection |
| 001206 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease |
| 001207 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
| 001208 |
Dominic C. Paviour [Royaume-Uni] ; Shona L. Price [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Nick C. Fox [Royaume-Uni] | Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations |
| 001214 |
Anthony E. Lang [Canada] ; Steven Gill [Royaume-Uni] ; Nik K. Patel [Royaume-Uni] ; Andres Lozano [Canada] ; John G. Nutt [États-Unis] ; Richard Penn [États-Unis] ; David J. Brooks [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Elena Moro [Canada] ; Peter Heywood [Canada] ; Matthew A. Brodsky [États-Unis] ; Kim Burchiel [États-Unis] ; Patrick Kelly [États-Unis] ; Arif Dalvi [États-Unis] ; Burton Scott [États-Unis] ; Mark Stacy [États-Unis] ; Dennis Turner [États-Unis] ; V. G. Frederich Wooten [États-Unis] ; William J. Elias [États-Unis] ; Edward R. Laws [États-Unis] ; Vijay Dhawan [États-Unis] ; A. Jon Stoessl [Canada] ; James Matcham [Royaume-Uni] ; Robert J. Coffey [États-Unis] ; Michael Traub [États-Unis] | Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease |
| 001220 |
Stephen B. Dunnett [Royaume-Uni] ; Anders Bjrklund [Suède] | Prospects for new restorative and neuroprotective treatments in Parkinson's disease |
| 001221 |
Felix Geser [Autriche] ; Gregor K. Wenning [Autriche] ; Klaus Seppi [Autriche] ; Michaela Stampfer-Kountchev [Autriche] ; Christoph Scherfler [Autriche] ; Martin Sawires [Autriche] ; Carolin Frick [Autriche] ; Jean-Pierre Ndayisaba [Autriche] ; Hanno Ulmer [Autriche] ; Maria T. Pellecchia [Italie] ; Paolo Barone [Italie] ; Hee T. Kim [Royaume-Uni] ; Juzar Hooker [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Adriana Cardozo [Espagne] ; Eduardo Tolosa [Espagne] ; Michael Abele [Allemagne] ; Thomas Klockgether [Allemagne] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Nicole Schimke [Allemagne] ; Karla M. Eggert [Allemagne] ; Wolfgang Oertel [Allemagne] ; Ruth Djaldetti [Israël] ; Werner Poewe [Autriche] | Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) |
| 001252 |
Paola Piccini [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | New developments of brain imaging for Parkinson's disease and related disorders |
| 001260 |
Anette Schrag [Royaume-Uni] ; Cristina Sampaio [Portugal] ; Nicholas Counsell [Royaume-Uni] ; Werner Poewe [Autriche] | Minimal clinically important change on the unified Parkinson's disease rating scale |
| 001277 |
Kallol Ray Chaudhuri [Royaume-Uni] ; Pablo Martinez-Martin [Espagne] ; Anthony H. V. Schapira [Royaume-Uni] ; Fabrizio Stocchi [Italie] ; Kapil Sethi [États-Unis] ; Per Odin [Allemagne] ; Richard G. Brown [Royaume-Uni] ; William Koller [États-Unis] ; Paolo Barone [Italie] ; Graeme Macphee [Royaume-Uni] ; Linda Kelly [Royaume-Uni] ; Martin Rabey [Israël] ; Doug Macmahon [Royaume-Uni] ; Sue Thomas [Royaume-Uni] ; William Ondo [États-Unis] ; David Rye [États-Unis] ; Alison Forbes [Royaume-Uni] ; Susanne Tluk [Royaume-Uni] ; Vandana Dhawan [Royaume-Uni] ; Annette Bowron [Royaume-Uni] ; Adrian J. Williams [Royaume-Uni] ; Charles W. Olanow [États-Unis] | International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study |
| 001313 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 001316 |
Eman M. Khedr [Égypte] ; John C. Rothwell [Royaume-Uni] ; Ola A. Shawky [Égypte] ; Mohamed A. Ahmed [Égypte] ; Ahmed Hamdy [Égypte] | Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease |
| 001317 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
| 001322 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 001330 |
Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Patricia Limousin [Royaume-Uni] ; Alim-Louis Benabid [France] | Deep brain stimulation for Parkinson's disease: Surgical issues |
| 001332 |
Andrew H. Evans [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Yen F. Tai [Royaume-Uni] ; Silke Appel [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Paola Piccini [Royaume-Uni] | Compulsive drug use linked to sensitized ventral striatal dopamine transmission |
| 001366 |
L. Ishihara [Royaume-Uni] ; C. Brayne [Royaume-Uni] | A systematic review of depression and mental illness preceding Parkinson's disease |
| 001370 |
Nicolas Pineda-Trujillo [Royaume-Uni, Colombie] ; Maria Apergi [Royaume-Uni] ; Sonia Moreno [Colombie] ; William Arias [Colombie] ; Suzanne Lesage [France] ; Alejandro Franco [Colombie] ; Diego Sepulveda-Falla [Colombie] ; David Cano [Colombie] ; Omar Buriticá [Colombie] ; David Pineda [Colombie] ; Carlos Santiago Uribe [Colombie] ; Justo Garcia De Yebenes [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] ; Alexis Brice [France] ; Gabriel Bedoya [Colombie] ; Francisco Lopera [Colombie] ; Andres Ruiz-Linares [Royaume-Uni, Colombie] | A genetic cluster of early onset Parkinson's disease in a Colombian population |
| 001405 |
Manoj Mishra [Royaume-Uni] ; Paul Durrington [Royaume-Uni] ; Mike Mackness [Royaume-Uni] ; Kirk W. Siddals ; Kalpana Kaushal ; Rob Davies [Royaume-Uni] ; Martin Gibson ; David W. Ray [Royaume-Uni] | The effect of atorvastatin on serum lipoproteins in acromegaly |
| 001411 |
N A Hamid [Royaume-Uni] ; R D Mitchell [Royaume-Uni] ; P. Mocroft [Royaume-Uni] ; G W M. Westby [Royaume-Uni] ; J. Milner [Royaume-Uni] ; H. Pall [Royaume-Uni] | Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement |
| 001417 |
Colum D. Mackinnon [États-Unis] ; Ruth M. Webb [Royaume-Uni] ; Paul Silberstein [Royaume-Uni] ; Steven Tisch [Royaume-Uni] ; Peter Asselman [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] | Stimulation through electrodes implanted near the subthalamic nucleus activates projections to motor areas of cerebral cortex in patients with Parkinson's disease |
| 001441 |
Louise M. Allan [Royaume-Uni] ; Clive G. Ballard [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] | Prevalence and Severity of Gait Disorders in Alzheimer's and Non‐Alzheimer's Dementias |
| 001448 |
A. C. Williams ; L. S. Cartwright [Royaume-Uni] ; D. B. Ramsden [Royaume-Uni] | Parkinson's disease: the first common neurological disease due to auto-intoxication? |
| 001461 |
Naheed L. Khan ; Shushant Jain ; John M. Lynch ; Nicola Pavese ; Patrick Abou-Sleiman ; Janice L. Holton ; Daniel G. Healy ; William P. Gilks ; Mary G. Sweeney ; Milan Ganguly ; Vaneesha Gibbons ; Sonia Gandhi ; Jenny Vaughan ; Louise H. Eunson ; Regina Katzenschlager ; Juliet Gayton ; Graham Lennox ; Tamas Revesz ; David Nicholl [Royaume-Uni] ; Kailash P. Bhatia ; Niall Quinn ; David Brooks ; Andrew Lees (neurologue) [Royaume-Uni] ; Mary B. Davis ; Paola Piccini ; Andrew B. Singleton [États-Unis] ; Nicholas W. Wood | Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data |
| 001462 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates |
| 001465 |
Sonia Gandhi [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | Molecular pathogenesis of Parkinson's disease |
| 001470 |
Peter P. Pramstaller [Italie, Allemagne] ; Michael G. Schlossmacher [États-Unis] ; Thomas S. Jacques [Royaume-Uni] ; Francesco Scaravilli [Royaume-Uni] ; Cordula Eskelson [Allemagne] ; Imelda Pepivani [États-Unis] ; Katja Hedrich [Allemagne] ; Susanna Adel [Allemagne] ; Melissa Gonzales-Mcneal [États-Unis] ; Rüdiger Hilker [Allemagne] ; Patricia L. Kramer [États-Unis] ; Christine Klein [Allemagne] | Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers |
| 001471 |
Catharine A. Winstanley [Royaume-Uni] ; Christelle Baunez [France] ; David E. H. Theobald [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] | Lesions to the subthalamic nucleus decrease impulsive choice but impair autoshaping in rats: the importance of the basal ganglia in Pavlovian conditioning and impulse control |
| 001472 |
Eilís Dowd [Royaume-Uni] ; Christelle Monville [Royaume-Uni] ; Eduardo M. Torres [Royaume-Uni] ; Liang-Fong Wong [Royaume-Uni] ; Mimoun Azzouz [Royaume-Uni] ; Nicholas D. Mazarakis [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model |
| 001474 |
Javed Ehtisham [Royaume-Uni] ; Hugh Watkins [Royaume-Uni] | Is Wolff‐Parkinson‐White Syndrome a Genetic Disease? |
| 001481 |
Mark Stacy [États-Unis] ; Annette Bowron [Royaume-Uni] ; Mark Guttman [Canada] ; Robert Hauser [États-Unis] ; Kim Hughes [Royaume-Uni] ; Jan Petter Larsen [Norvège] ; Peter Lewitt [États-Unis] ; Wolfgang Oertel [Allemagne] ; Niall Quinn [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie] | Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment |
| 001499 |
M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France] | Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study |
| 001509 |
Philippe Remy [France] ; Miroslava Doder [France] ; Andrew Lees (neurologue) [Royaume-Uni, France] ; Nora Turjanski [France] ; David Brooks [France] | Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system |
| 001513 |
Jordi Clarimon [États-Unis] ; Janel Johnson [États-Unis] ; Okan Dogu [Turquie] ; Wagner Horta [Brésil] ; Naheed Khan [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [États-Unis] ; Andrew Singleton [États-Unis] | Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease |
| 001516 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
| 001526 |
Serge Pinto [France, Royaume-Uni] ; Michèle Gentil [France] ; Paul Krack [France] ; Paul Sauleau [France] ; Valérie Fraix [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech |
| 001540 |
Dag Aarsland [Norvège] ; Julia Zaccai [Royaume-Uni] ; Carol Brayne [Royaume-Uni] | A systematic review of prevalence studies of dementia in Parkinson's disease |
| 001562 |
S E Hughes [Royaume-Uni] | The pathology of hypertrophic cardiomyopathy |
| 001564 |
Rina Bandopadhyay [Royaume-Uni] ; Ann E. Kingsbury [Royaume-Uni] ; Mark R. Cookson ; Andrew R. Reid ; Ian M. Evans ; Andrew D. Hope ; Alan M. Pittman ; Tammaryn Lashley ; Rosa Canet-Aviles ; David W. Miller ; Chris Mclendon ; Catherine Strand ; Andrew J. Leonard ; Patrick M. Abou-Sleiman ; Daniel G. Healy ; Hiroyashi Ariga ; Nicholas W. Wood ; Rohan De Silva ; Tamas Revesz ; John A. Hardy ; Andrew Lees (neurologue) [Royaume-Uni] | The expression of DJ‐1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease |
| 001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001583 |
Iracema Leroi [Royaume-Uni, États-Unis] ; Jason Brandt [États-Unis] ; Stephen G. Reich [États-Unis] ; Constantine G. Lyketsos [États-Unis] ; Stephen Grill [États-Unis] ; Richard Thompson [États-Unis] ; Laura Marsh [États-Unis] | Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease |
| 001602 |
Elanor C. Hinton [Royaume-Uni] ; John A. Parkinson [Royaume-Uni] ; Anthony J. Holland [Royaume-Uni] ; F. Sergio Arana [Royaume-Uni] ; Angela C. Roberts [Royaume-Uni] ; Adrian M. Owen [Royaume-Uni] | Neural contributions to the motivational control of appetite in humans |
| 001613 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 001621 |
C. Panter-Brick [Royaume-Uni] ; P. G. Lunn [Royaume-Uni] ; R. Goto [Royaume-Uni] ; C. M. Wright [Royaume-Uni] | Immunostimulation and growth faltering in UK infants |
| 001629 |
M. Martinez [France] ; A. Brice [France] ; J R Vaughan [Royaume-Uni] ; A. Zimprich [Allemagne] ; M M B. Breteler [Pays-Bas] ; G. Meco [Italie] ; A. Filla [Italie] ; M J Farrer [États-Unis] ; C. Bétard [France] ; J. Hardy [États-Unis] ; G. De Michele [Italie] ; V. Bonifati [Italie] ; B. Oostra [Pays-Bas] ; T. Gasser [Allemagne] ; N W Wood [Royaume-Uni] ; A. Dürr [France] | Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease |
| 001637 |
Catherine Lozza [France] ; Jean-Claude Baron [France, Royaume-Uni] ; David Eidelberg [États-Unis] ; Marc J. Mentis [États-Unis] ; Maren Carbon [États-Unis] ; Rose-Marie Marié [France] | Executive processes in Parkinson's disease: FDG‐PET and network analysis |
| 001645 |
Maaike Bakker [Pays-Bas] ; Rianne A. J. Esselink [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Patricia Limousin-Dowsey [Royaume-Uni] ; Hans D. Speelman [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Effects of stereotactic neurosurgery on postural instability and gait in Parkinson's disease |
| 001655 |
Dominic C. Paviour [Royaume-Uni] ; Robert A. H. Surtees [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Diagnostic considerations in juvenile parkinsonism |
| 001673 |
Carl E. Clarke [Royaume-Uni] | A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? |
| 001685 |
Regina Katzenschlager [Royaume-Uni] ; Adriana Cardozo [Espagne] ; M. Rosario Avila Cobo [Espagne] ; Eduardo Tolosa [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] | Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders |
| 001708 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study |
| 001725 |
R. J. Scaramuzzi [Royaume-Uni] ; D. J. Baker [Royaume-Uni] | Possible therapeutic benefits of adenosine‐potentiating drugs in reducing age‐related degenerative disease in dogs and cats |
| 001733 |
Peter Jenner [Royaume-Uni] | Oxidative stress in Parkinson's disease |
| 001742 |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
| 001753 |
David J. Brooks [Royaume-Uni] | Imaging end points for monitoring neuroprotection in Parkinson's disease |
| 001757 |
Ebba Lohmann [France] ; Magali Periquet [France] ; Vincenzo Bonifati [Italie] ; Nick W. Wood [Royaume-Uni] ; Giuseppe De Michele [Italie] ; Anne-Marie Bonnet [France] ; Valérie Fraix [France] ; Emmanuel Broussolle [France] ; Martin W. I. M. Horstink [Pays-Bas] ; Marie Vidailhet [France] ; Patrice Verpillat [France] ; Thomas Gasser [Allemagne] ; David Nicholl [Royaume-Uni] ; Hélio Teive [Brésil] ; Salmo Raskin [Brésil] ; Olivier Rascol [France] ; Alain Destée [France] ; Merle Ruberg [France] ; Francesca Gasparini [France] ; Giuseppe Meco [Italie] ; Yves Agid [France] ; Alexandra Durr [France] ; Alexis Brice [France] | How much phenotypic variation can be attributed to parkin genotype? |
| 001767 |
Marwan I. Hariz [Suède, Royaume-Uni] | From functional neurosurgery to “interventional” neurology: Survey of publications on thalamotomy, pallidotomy, and deep brain stimulation for Parkinson's disease from 1966 to 2001 |
| 001772 |
Mark Edwards [Royaume-Uni] ; Geoffrey Schott [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] | Episodic focal lingual dystonic spasms |
| 001774 |
D J Brooks [Royaume-Uni] ; H. Sagar [Royaume-Uni] | Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study |
| 001775 |
Paola Piccini [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | Endogenous dopamine release after pharmacological challenges in Parkinson's disease |
| 001778 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 001799 |
David Mckee [Royaume-Uni] ; Paul Talbot [Royaume-Uni] | Chorea as a presenting feature of variant Creutzfeldt‐Jakob disease |
| 001814 |
Willibald Gerschlager [Autriche, Royaume-Uni] ; Gerhard Bencsits [Autriche] ; Walter Pirker [Autriche] ; Bastiaan R. Bloem [Royaume-Uni, Pays-Bas] ; Susanne Asenbaum [Autriche] ; Daniella Prayer [Autriche] ; Jan C. M. Zijlmans [Royaume-Uni] ; Martha Hoffmann [Autriche] ; Thomas Brücke [Autriche] | [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease |
| 001816 |
Simon G. Parkin [Royaume-Uni] ; Ralph P. Gregory [Royaume-Uni] ; Richard Scott [Royaume-Uni] ; Peter Bain [Royaume-Uni] ; Peter Silburn [Australie] ; Bruce Hall [Australie] ; Richard Boyle [Australie] ; Carole Joint [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients |
| 001821 |
T. Foltynie [Royaume-Uni] ; S. Sawcer [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; R A Barker [Royaume-Uni] | The genetic basis of Parkinson's disease |
| 001827 |
K R Chaudhuri [Royaume-Uni] ; S. Pal [Royaume-Uni] ; A. Dimarco [Royaume-Uni] ; C. Whately-Smith ; K. Bridgman [Royaume-Uni] ; R. Mathew [Royaume-Uni] ; F R Pezzela [Italie] ; A. Forbes [Royaume-Uni] ; B. Högl [Allemagne] ; C. Trenkwalder [Allemagne] | The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease |
| 001831 |
Katherine H. O. Deane [Royaume-Uni] ; Caroline Ellis-Hill [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Renata Whurr [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] ; E. Diane Playford [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of paramedical therapies for Parkinson's disease |
| 001836 |
C. Parkinson ; W. M. Drake [Royaume-Uni] ; G. Wieringa ; A. P. Yates [Royaume-Uni] ; G. M. Besser [Royaume-Uni] ; P. J. Trainer | Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly |
| 001854 |
Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Jan Booij [Pays-Bas] ; Jaap Valk [Pays-Bas] ; Andrew Lees (neurologue) [Royaume-Uni] ; Martin Horstink [Pays-Bas] | Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway |
| 001914 |
Günther Deuschl [Allemagne] ; Peter Bain [Royaume-Uni] | Deep brain stimulation for trauma: Patient selection and evaluation |
| 001921 |
Andrew West [États-Unis] ; Magali Periquet [France] ; Sarah Lincoln [États-Unis] ; Christoph B. Lücking [France, Allemagne] ; David Nicholl [Royaume-Uni] ; Vincenzo Bonifati ; Nina Rawal [France] ; Thomas Gasser [Allemagne] ; Ebba Lohmann [France] ; Jean-François Deleuze [France] ; Demetrius Maraganore [États-Unis] ; Allan Levey [Géorgie (pays)] ; Nick Wood [Royaume-Uni] ; Alexandra Dürr [France] ; John Hardy [États-Unis] ; Alexis Brice [France] ; Matt Farrer [États-Unis] | Complex relationship between Parkin mutations and Parkinson disease |
| 001936 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients |
| 001937 |
G C Pluck [Royaume-Uni] ; R G Brown | Apathy in Parkinson’s disease |
| 001951 |
Barry J. Everitt [Royaume-Uni] ; Anthony Dickinson [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] | The neuropsychological basis of addictive behaviour |
| 001962 |
Karen Sleeman [Royaume-Uni] ; Kyle Knox [Royaume-Uni] ; Robert George [Royaume-Uni] ; Elizabeth Miller [Royaume-Uni] ; Pauline Waight [Royaume-Uni] ; David Griffiths [Royaume-Uni] ; A. Efstratiou [Royaume-Uni] ; K. Broughton [Royaume-Uni] ; Richard T. Mayon-White [Royaume-Uni] ; E. R. Moxon [Royaume-Uni] ; D. W. Crook [Royaume-Uni] | Invasive Pneumococcal Disease in England and Wales: Vaccination Implications |
| 001969 |
Lori L. Jennings [Canada] ; Chunhai Hao [Canada] ; Miguel A. Cabrita [Canada] ; Mark F. Vickers [Canada] ; Stephen A. Baldwin [Royaume-Uni] ; James D. Young [Canada] ; Carol E. Cass [Canada] | Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system |
| 001998 |
Ernest W. Lau [Royaume-Uni] ; G. André Ng [Royaume-Uni] ; Michael J. Griffith [Royaume-Uni] | Variability in the Manifestation of Pre‐excited Atrial Fibrillation: Its Quantification, Theoretical Origin, and Diagnostic Potential |
| 001A02 |
M C Parkinson ; S J Harland ; P. Harnden ; A. Sandison [Royaume-Uni] | The role of the histopathologist in the management of testicular germ cell tumour in adults |
| 001A48 |
Enza Maria Valente [Royaume-Uni] ; Anna Rita Bentivoglio [Italie] ; Peter H. Dixon [Royaume-Uni] ; Alessandro Ferraris [Italie] ; Tamara Ialongo [Italie] ; Marina Frontali [Italie] ; Alberto Albanese [Italie] ; Nicholas W. Wood [Royaume-Uni] | Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36 |
| 001A58 |
H. Watkins [Royaume-Uni] | Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management |
| 001A90 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001A95 |
S. Bostantjopoulou [Grèce] ; Z. Katsarou [Grèce] ; A. Papadimitriou [Grèce] ; V. Veletza [Grèce] ; G. Hatzigeorgiou [Grèce] ; A. Lees [Royaume-Uni] | Clinical features of parkinsonian patients with the α‐synuclein (G209A) mutation |
| 001B18 |
Zhang-Yan Tong [Royaume-Uni] ; Ann E. Kingsbury [Royaume-Uni] ; Oliver J. F Foster [Royaume-Uni] | Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson’s disease |
| 001B60 |
Maria Grazia Spillantini [Royaume-Uni] ; Michel Goedert [Royaume-Uni] | The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy |
| 001C39 |
Anette Schrag [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Dyskinesias and motor fluctuations in Parkinson's disease |
| 001C42 |
Ram N Leiguarda [Argentine] ; Marcelo Merello [Argentine] ; Jorge Balej [Argentine] ; Sergio Starkstein [Argentine] ; Martín Nogues [Argentine] ; C. David Marsden [Royaume-Uni] | Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy |
| 001C70 |
David S. Fedson [France] ; J. Anthony [Royaume-Uni] ; G. Scott [États-Unis] | The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known |
| 001D03 |
Karen M. Rudolph [États-Unis] ; Marilyn J. Crain [Royaume-Uni] ; Alan J. Parkinson [États-Unis] ; Marilyn C. Roberts | Characterization of a Multidrug-Resistant Clone of Invasive Streptococcus pneumoniae Serotype 6B in Alaska Using Pulsed-Field Gel Electrophoresis and PspA Serotyping |
| 001D43 |
Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges |
| 001D63 |
Y. Ben-Shlomo [Royaume-Uni] ; J. Head [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Mortality in DATATOP |
| 001D65 |
C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni] | Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum |
| 001D72 |
Taylor [Royaume-Uni] ; Beerahee [Royaume-Uni] ; Citerone [États-Unis] ; Cyronak [États-Unis] ; Leigh [Royaume-Uni] ; Fitzpatrick [Royaume-Uni] ; Lopez‐Gil [Royaume-Uni] ; Vakil [Royaume-Uni] ; Burns [Royaume-Uni] ; Lennox [Royaume-Uni] | Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease |
| 001D80 |
R. G. Brown [Royaume-Uni] ; P. Limousin Dowsey [Royaume-Uni, France] ; P. Brown [Royaume-Uni] ; M. Jahanshahi [Royaume-Uni] ; Pierre Pollak [France] ; Alim-Louis Benabid [France] ; M. C. Rodriguez-Oroz [Espagne] ; J. Obeso [Espagne] ; J. C. Rothwell [Royaume-Uni] | Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease |
| 001E30 |
C. H. Robinson [Royaume-Uni] ; P. J. Fisher [Royaume-Uni] ; B. C. Sutton [Royaume-Uni] | Fungal biodiversity in dead leaves of fertilized plants of Dryas octopetala from a high arctic site |
| 001E46 |
Anette Schrag [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] ; Richard Brown [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality |
| 001E48 |
Jenner [Royaume-Uni] ; C. Warren Olanow | Understanding cell death in parkinson's disease |
| 001E53 |
Brooks [Royaume-Uni] | The early diagnosis of parkinson's disease |
| 001E58 |
J. M Henderson [Royaume-Uni] ; S. B Dunnett [Royaume-Uni] | Targeting the subthalamic nucleus in the treatment of Parkinson’s disease |
| 001E63 |
Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study |
| 001E69 |
Andrew G. Riedl [Royaume-Uni] ; Paul M. Watts [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | P450 enzymes and Parkinson's disease: The story so far |
| 001E79 |
M. Gu [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; J. W. Taanman [Royaume-Uni] ; Schapira [Royaume-Uni] | Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease |
| 001E93 |
Oliver Bandmann [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Wood [Royaume-Uni] | Genetic aspects of Parkinson's disease |
| 001F05 |
C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] ; David Brooks [Royaume-Uni] | Dopamine agonists and neuroprotection in parkinson's disease |
| 001F13 |
Ronald K. B. Pearce [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset |
| 001F16 |
A. Charlett [Royaume-Uni] ; R. J. Dobbs ; A. G. Purkiss ; D. J. Wrighe ; D. W. Peterson [Royaume-Uni] ; C. Weller ; S. M. Dobbs | Cortisol is higher in parkinsonism and associated with gait deficit |
| 001F34 |
John Parkinson [Royaume-Uni] ; Andy Brass [Royaume-Uni] ; Giles Canova [France] ; Yves Brechet [France] | The mechanical properties of simulated collagen fibrils |
| 001F36 |
Crispin Jenkinson [Royaume-Uni] ; Ray Fitzpatrick [Royaume-Uni] ; Viv Peto [Royaume-Uni] ; Richard Greenhall [Royaume-Uni] ; Nigel Hyman [Royaume-Uni] | The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score |
| 001F38 |
O. A. Obel [Royaume-Uni] ; A. J. Camm [Royaume-Uni] | Supraventricular tachycardia |
| 002033 |
V. V. Myllyl [Finlande] ; M. Jackson [Royaume-Uni] ; J. P. Larsen [Norvège] ; H. Baas [Allemagne] | Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial |
| 002037 |
Piccini [Royaume-Uni] ; P. K. Morrish [Royaume-Uni] ; N. Turjanski [Royaume-Uni] ; G. V. Sawle [Royaume-Uni] ; D. J. Burn [Royaume-Uni] ; R. A. Weeks [Royaume-Uni] ; M. H. Mark [États-Unis] ; D. M. Maraganore [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] | Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study |
| 002064 |
Timothy M. Cox [Royaume-Uni] ; J. Paul Schofield [Royaume-Uni] | 3 Gaucher's disease: clinical features and natural history |
| 002065 |
M R Feneley [Royaume-Uni] ; M P Young [Royaume-Uni] ; C. Chinyama [Royaume-Uni] ; R S Kirby [Royaume-Uni] ; M C Parkinson [Royaume-Uni] | Ki-67 expression in early prostate cancer and associated pathological lesions. |
| 002073 |
Oliver Bandmann [Royaume-Uni] ; Sue Daniel [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] ; Anita E. Harding [Royaume-Uni] | The GTP-cyclohydrolase I gene in atypical Parkinsonian patients: a clinico-genetic study |
| 002114 |
N. A. Parkinson [Royaume-Uni] ; A. F. James [Royaume-Uni] ; B. M. Hendry [Royaume-Uni] | Actions of endothelin-1 on calcium homeostasis in Madin—Darby canine kidney tubule cells |
| 002138 |
Corcos [États-Unis, Royaume-Uni] ; Chiung-Mei Chen [Taïwan, Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; John Mcauley [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] | Strength in Parkinson's disease: Relationshp to rate of force generation and clinical status |
| 002151 |
F. Tison [France] ; K. Wenning [Autriche] ; A. Volonte [Italie] ; R. Poewe [Autriche] ; P. Henry [France] ; P. Quinn [Royaume-Uni] | Pain in multiple system atrophy |
| 002166 |
C. Rickards [Royaume-Uni] ; F. W. J. Cody [Royaume-Uni] | Increased use of target cues during visuo‐motor tracking in Parkinson's disease |
| 002176 |
Christian Spenger [Suisse] ; K. Haque [Royaume-Uni] ; Lorenz Studer [Suisse] ; Ljudmila Evtouchenko [Suisse] ; Bendicht Wagner [Suisse] ; Beatrice Bühler [Suisse] ; Urban Lendahl [Suède] ; B. Dunnett [Royaume-Uni] ; W. Seiler [Suisse] | Fetal ventral mesencephalon of human and rat origin maintained in vitro and transplanted to 6-hydroxydopamine-lesioned rats gives rise to grafts rich in dopaminergic neurons |
| 002211 |
Waterston [Royaume-Uni] ; Graham R. Barnes [Royaume-Uni] ; Madeleine A. Grealy [Royaume-Uni] ; Sue Collins [Royaume-Uni] | Abnormalities of smooth eye and head movement control in parhson's disease |
| 002213 |
Edith Sim [Royaume-Uni] ; Lesley A. Stanley [Royaume-Uni] ; Angela Risch [Royaume-Uni] ; Peter Thygesen [Danemark] | Xenogenetics in multifactorial disease susceptibility |
| 002252 |
J. G. De Yébenes ; J. L. Sarasa ; S. E. Daniel [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Familial progressive supranuclear palsy |
| 002273 |
F. Tison ; G. K. Wenning ; S. E. Daniel [Royaume-Uni] ; N. P. Quinn | The pathophysiology of parkinsonism in multiple system atrophy |
| 002276 |
Jane E. Parkinson [Royaume-Uni] ; Christopher M. Sanderson [Royaume-Uni] ; Geoffrey L. Smith [Royaume-Uni] | The Vaccinia Virus A38L Gene Product Is a 33-kDa Integral Membrane Glycoprotein |
| 002277 |
Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Teresa A. Chmura [États-Unis] ; Stanley Fahn [États-Unis] ; Harold L. Klawans [États-Unis] ; C. David Marsden [Royaume-Uni] | Teaching tape for the motor section of the unified Parkinson's disease rating scale |
| 002293 |
C. Trenkwalder [Royaume-Uni] ; W. Paulus [Royaume-Uni] ; S. Krafczyk [Royaume-Uni] ; M. Hawken [Royaume-Uni] ; W. H. Oertel [Royaume-Uni] ; Th. Brandt [Royaume-Uni] | Postural stability differentiates “lower body” from idiopathic parkinsonism |
| 002335 |
Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease? A review of the evidence |
| 002336 |
C. A. Davie [Royaume-Uni] ; G. K. Wenning [Royaume-Uni] ; G. J. Barker [Royaume-Uni] ; P. S. Tofts [Royaume-Uni] ; B. E. Kendall [Royaume-Uni] ; N. Quinn [Royaume-Uni] ; W. I. Mcdonald [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; D. H. Miller [Royaume-Uni] | Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy |
| 002395 |
Haug [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Geoffrey B. Arden [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Walter Paulus [Allemagne] | Visual thresholds to low‐contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease |
| 002400 |
S. Enochs [États-Unis] ; T. Sarna [Pologne] ; L. Zecca [Italie] ; A. Riley [Royaume-Uni] ; M. Swartz [États-Unis] | The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis |
| 002442 |
H. Ikeda [Royaume-Uni] ; G. M. Head [Royaume-Uni] ; C. J K. Ellis [Royaume-Uni] | Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study |
| 002457 |
Jeswinder Sian ; David T. Dexter ; Andrew Lees (neurologue) [Royaume-Uni] ; Susan Daniel [Royaume-Uni] ; Yves Agid [France] ; France Javoy-Agid [France] ; Peter Jenner ; C. David Marsden [Royaume-Uni] | Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia |
| 002464 |
P. D. Griffiths [Royaume-Uni] ; R. H. Perry [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] | A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease |
| 002476 |
Jennian F. Geddes ; Andrew J. Hughes [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Susan E. Daniel [Royaume-Uni] | Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles |
| 002481 |
David J. Brooks [Royaume-Uni] | Functional imaging in relation to parkinsonian syndromes |
| 002495 |
Peter Jenner [Royaume-Uni] | Maladie de Parkinson: mécanismes physiopathologiques et effets du piribédil |
| 002503 |
D. Malcolm [Royaume-Uni] ; J. Garratt [Royaume-Uni] ; John Camm [Royaume-Uni] | The therapeutic and diagnostic cardiac electrophysiological uses of adenosine |
| 002527 |
G. Kennedy [Royaume-Uni] ; Pring [Royaume-Uni] ; R. Fawcus [Royaume-Uni] | No place for motor speech acts in the assessment of dysphagia? Intelligibility and swallowing difficulties in stroke and Parkinson's disease patients |
| 002540 |
S. Markus [Royaume-Uni] ; M. Tomkins [Royaume-Uni] ; M. Stern [Royaume-Uni] | Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters |
| 002568 |
J. Till [Royaume-Uni] ; C. Wren [Royaume-Uni] | Atrial flutter in the fetus and young infant: an association with accessory connections. |
| 002610 |
Brooks [Royaume-Uni] ; V. Ibanez [Royaume-Uni] ; G. V. Sawle [Royaume-Uni] ; E. D. Playford [Royaume-Uni] ; N. Quinn [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; R. Bannister [Royaume-Uni] ; R. S. J. Frackowiak [Royaume-Uni] | Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography |
| 002615 |
J. E. Deal [Royaume-Uni] ; M. F. Snell [Royaume-Uni] ; T. M. Barratt [Royaume-Uni] ; M. J. Dillon [Royaume-Uni] | Renovascular disease in childhood |
| 002620 |
Peter Jenner [Royaume-Uni] | Parkinson's disease: pathological mechanisms and actions of piribedil |
| 002624 |
Jenner [Royaume-Uni] ; D. T. Dexter [Royaume-Uni] ; J. Sian [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease |
| 002649 |
Dexter [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia |
| 002752 |
J. A. Johnson [Royaume-Uni] ; T. R. Pring [Royaume-Uni] | Speech therapy and Parkinson's disease: A review and further data |
| 002792 |
W R Gibb [Royaume-Uni] ; C Q Mountjoy [Royaume-Uni] ; D M Mann [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | A pathological study of the association between Lewy body disease and Alzheimer's disease. |
| 002798 |
A. G. M. Canavan [Royaume-Uni] ; R. E. Passingham [Royaume-Uni] ; C. D. Marsden ; N. Quinn [Royaume-Uni] ; M. Wyke ; C. E. Polkey [Royaume-Uni] | The performance on learning tasks of patients in the early stages of Parkinson's disease |
| 002799 |
J. P. R. Dick [Royaume-Uni] ; J. C. Rothwell [Royaume-Uni] ; B. L. Day [Royaume-Uni] ; R. Cantello [Royaume-Uni] ; O. Buruma [Royaume-Uni] ; M. Gioux [Royaume-Uni] ; R. Benecke [Royaume-Uni] ; A. Berardelli [Royaume-Uni] ; P. D. Thompson [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | THE BEREITSCHAFTSPOTENTIAL IS ABNORMAL IN PARKINSON'S DISEASE |
| 002806 |
A. R. Crossman [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; S. Boyce [Royaume-Uni] ; M. R. Luquin [Royaume-Uni] ; M. A. Sambrook [Royaume-Uni] | Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey |
| 002818 |
W. R. G. Gibb ; Andrew Lees (neurologue) [Royaume-Uni] | THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE |
| 002849 |
O. Isacson [Royaume-Uni] ; D. Riche [France] ; P. Hantraye [France] ; V. Sofroniew [Royaume-Uni] ; M. Maziere [France] | A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen |
| 002850 |
E. Rowland [Royaume-Uni] ; K. Robinson [Royaume-Uni] ; S. Edmondson [Royaume-Uni] ; D M Krikler [Royaume-Uni] ; H H Bentall [Royaume-Uni] | Cryoablation of the accessory pathway in Wolff-Parkinson-White syndrome: initial results and long term follow up. |
| 002851 |
A. M. Gotham [Royaume-Uni] ; R. G. Brown [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | ‘FRONTAL’ COGNITIVE FUNCTION IN PATIENTS WITH PARKINSON'S DISEASE ‘ON’AND ‘OFF’ LEVODOPA |
| 002860 |
R. G. Brown [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | INTERNAL VERSUS EXTERNAL CUES AND THE CONTROL OF ATTENTION IN PARKINSON'S DISEASE |
| 002877 |
E. Sofic [Allemagne] ; P. Riederer [Allemagne] ; H. Heinsen [Allemagne] ; H. Beckmann [Allemagne] ; P. Reynolds [Royaume-Uni] ; G. Hebenstreit [Autriche] ; H. Youdim [Israël] | Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain |
| 002878 |
A. P. Weetman [Royaume-Uni] ; A. K. So [Royaume-Uni] ; C. A. Warner [Royaume-Uni] ; L. Foroni [Royaume-Uni] ; P. Fells [Royaume-Uni] ; B. Shine [Royaume-Uni] | IMMUNOGENETICS OF GRAVES' OPHTHALMOPATHY |
| 002881 |
Brian Parkinson [Royaume-Uni] ; Lynne Colgan [Royaume-Uni] | False autonomic feedback: Effects of attention to feedback on ratings of pleasant and unpleasant target stimuli |
| 002885 |
Poewe [Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern [Royaume-Uni] | Dystonia in parkinson's disease: Clinical and pharmacological features |
| 002888 |
N. Cooper [Royaume-Uni] ; F. Clayton [Royaume-Uni] | DNA polymorphism and the study of disease associations |
| 002908 |
D. Rogers ; Andrew Lees (neurologue) [Royaume-Uni] ; Eileen Smith ; M. Trimble ; G. M. Stern | BRADYPHRENIA IN PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE ILLNESS |
| 002910 |
Niall Quinn [Royaume-Uni] ; Peter Critchley [Royaume-Uni] ; Marsden [Royaume-Uni] | Young onset Parkinson's disease |
| 002915 |
G. Gibb [Royaume-Uni] ; J. Lees [Royaume-Uni] | The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome |
| 002943 |
R. G Brown [Royaume-Uni] ; C. D Marsden [Royaume-Uni] | VISUOSPATIAL FUNCTION IN PARKINSON'S DISEASE |
| 002950 |
Andrew Lees (neurologue) [Royaume-Uni] | L-Dopa Treatment and Parkinson's Disease |
| 002956 |
Niall P. Quinn [Royaume-Uni] ; Martin N. Rossor [Royaume-Uni] ; C David Marsden [Royaume-Uni] | DEMENTIA AND PARKINSON'S DISEASE — PATHHOLOGICAL AND NEUROCHEMICAL CONSIDERATIONS |
| 002971 |
Brian Parkinson [Royaume-Uni] ; R. Manstead [Royaume-Uni] | False autonomic feedback: Effects of attention to feedback on ratings of erotic stimuli |
| 002A09 |
R. L. G. Sutcliffe [Royaume-Uni] ; R. Prior [Royaume-Uni] ; B. Mawby [Royaume-Uni] ; W. J. Mcquillan [Royaume-Uni] | Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability |
| 002A30 |
R. S. F. Schilling [Royaume-Uni] | More Effective Prevention in Occupational Health Practice? |
| 002A69 |
Andrew Lees (neurologue) [Royaume-Uni] ; Eileen Smith | COGNITIVE DEFICITS IN THE EARLY STAGES OF PARKINSON'S DISEASE |
| 002B15 |
A. E. Lang [Royaume-Uni, Canada] ; N. Quinn [Royaume-Uni] ; S. Brincat [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; Parkes [Royaume-Uni] | Pergolide in late‐stage Parkinson disease |
| 002B20 |
A. C. Bird [Royaume-Uni] | INVESTIGATION OF RETINITIS PIGMENTOSA |
| 002B27 |
A. E. Lang [Royaume-Uni, Canada] ; Marsden [Royaume-Uni] ; J. A. Obeso [Royaume-Uni] ; J. D. Parkes [Royaume-Uni] | Alcohol and Parkinson disease |
| 002B41 |
C. J. Fowler [Irlande (pays)] ; L. Oreland [Suède] ; B. A. Callingham [Royaume-Uni] | The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J‐508: their properties and applications |
| 002B48 |
J. D. Parkes ; M. Schachter ; C. D. Marsden ; B. Smith [Royaume-Uni] ; A. Wilson [Royaume-Uni] | Lisuride in parkinsonism |
| 002B68 |
David Parkinson [Royaume-Uni] ; Geoffrey A. Lyles [Royaume-Uni] ; Barbara J. Browne [Royaume-Uni] ; Brian A. Callingham [Royaume-Uni] | Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver |
| 002C24 |
I. Bartram [Royaume-Uni] | Radiology in the current assessment of ulcerative colitis |
| 002C70 |
Hugh Trowell [Ouganda, Royaume-Uni] ; Neil Painter [Ouganda, Royaume-Uni] ; Denis Burkitt [Ouganda, Royaume-Uni] | Aspects of the epidemiology of diverticular disease and ischemic heart disease |
| 002D37 |
J. W. Warburton [Royaume-Uni] | Memory disturbance and the Parkinson syndrome |
| 002D76 |
George J. Cunningham [Royaume-Uni] ; Thomas Parkinson [Royaume-Uni] | Diffuse Cystic Lungs of Granulomatous Origin |
